#COVID-19 treatment

Two scientists cooperating while examining antiviral drug in a test tube at laboratory

FDA Approves Remdesivir for Hospitalized COVID-19 Patients

NIH Study Aims To Identify Promising COVID-19 Treatments for Larger Trials

How is COVID-19 treated?

FDA Approves Remdesivir for Hospitalized COVID-19 Patients

NIH Study Aims To Identify Promising COVID-19 Treatments for Larger...

How is COVID-19 treated?

SARS-CoV-2 virus particles within the endosomes of a nasal olfactory epithelial cell

SARS-CoV-2 Antigen Levels Linked to Patient Outcomes

Higher levels of viral antigens in the blood correlated with more severe disease.

CDC Streamlines COVID-19 Guidance

The update aims to help the public better protect themselves and understand their risk.

SARS-CoV-2, the coronavirus that causes COVID-19

Interferon Treatment May Reduce Severity of COVID-19 in People With Certain Genetic Factors

People of European or African ancestry who were hospitalized for COVID-19 are more likely to carry particular genetic variants.

Immune Modulator Drugs Improved Survival for People Hospitalized With COVID-19

Two drugs widely used to treat certain autoimmune diseases substantially improved clinical status and reduced deaths.

Scientists Identify Characteristics to Better Define Long COVID

Using machine learning, researchers find patterns in electronic health record data to better identify those likely to have the condition.

3D model of SARS-CoV2 coronavirus (back) and its spike protein (front) that enables the virus to enter human cells.

Intranasal Proteins Could Protect Against COVID-19 Variants

With further testing, the antiviral proteins might be used as a nasal spray to prevent or treat COVID-19.

FDA Approves First COVID-19 Treatment for Young Children

Remdesivir (Veklury) is now approved for kids ages 28 days to 12 years.

Nasal Antiviral Blocks SARS-CoV-2 Infection in Mice

Antiviral drugs that target host cells may work against many existing and future variants of the virus that causes COVID-19.

How the Test-to-Treat Pillar of the U.S. COVID Strategy Is Failing Patients

Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.

Non-English Speakers With COVID-19 Susceptible to Worse Health Outcomes

Racial and ethnic minorities were disproportionately affected by COVID-19 during the first year of the pandemic.

The End of the COVID Emergency Could Mean a Huge Loss of Health Insurance

The United States might see one of the steepest increases in the country’s uninsured rate in years.

Antibodies attacking SARS-CoV-2, the coronavirus that causes COVID-19

To Prevent Future COVID Variants, We Must Protect Those Most At Risk

Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.

The CDC’s New Guidelines on COVID Risk and Masking Send Confounding Signals

The CDC’s move triggered mixed feelings from the public and laid bare a split within the health care community.

FDA OKs Second COVID Antiviral Pill for Limited Use

Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.

FDA Authorizes First Antiviral Pill for COVID-19

Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.

FDA Advisors Recommend Antiviral Pill for Early COVID Treatment

Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.

#COVID-19 treatment

FDA Approves Remdesivir for Hospitalized COVID-19 Patients

NIH Study Aims To Identify Promising COVID-19 Treatments for Larger Trials

How is COVID-19 treated?

FDA Approves Remdesivir for Hospitalized COVID-19 Patients

NIH Study Aims To Identify Promising COVID-19 Treatments for Larger...

How is COVID-19 treated?

SARS-CoV-2 Antigen Levels Linked to Patient Outcomes

CDC Streamlines COVID-19 Guidance

Interferon Treatment May Reduce Severity of COVID-19 in People With Certain Genetic Factors

Immune Modulator Drugs Improved Survival for People Hospitalized With COVID-19

Scientists Identify Characteristics to Better Define Long COVID

Intranasal Proteins Could Protect Against COVID-19 Variants

FDA Approves First COVID-19 Treatment for Young Children

Nasal Antiviral Blocks SARS-CoV-2 Infection in Mice

How the Test-to-Treat Pillar of the U.S. COVID Strategy Is Failing Patients

Non-English Speakers With COVID-19 Susceptible to Worse Health Outcomes

The End of the COVID Emergency Could Mean a Huge Loss of Health Insurance

To Prevent Future COVID Variants, We Must Protect Those Most At Risk

The CDC’s New Guidelines on COVID Risk and Masking Send Confounding Signals

FDA OKs Second COVID Antiviral Pill for Limited Use

FDA Authorizes First Antiviral Pill for COVID-19

FDA Advisors Recommend Antiviral Pill for Early COVID Treatment

Ask COVID Health

Features